FDA Grants Orphan Drug Designation to Immuneering's IMM-1-104 for Pancreatic Cancer Treatment
Immuneering Corporation, a clinical-stage oncology company focused on developing universal RAS/RAF medicines for a broad range of cancer patients, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 for the treatment of pancreatic cancer. IMM-1-104 is currently in a Phase 2a clinical trial for patients with advanced solid tumors, including pancreatic cancer. Recent initial response data for first-line pancreatic cancer patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel has been positive. Publish Date: 15-10-2024 Source: Immuneering Corporation Pancreatic cancer, specifically pancreatic ductal carcinoma, originates from the pancreatic duct cells. This type of cancer can manifest as adenocarcinoma, serous, seromucinous, or mucinous variations. Notable tumor markers associated with pancreatic cancer are CEA and CA 19-9. The predominant form of pancreatic cancer is adenocarc...